Status:

NOT_YET_RECRUITING

Preoperative Risk Evaluation and Per ERAS Intervention in the Chinese Elderly Patients Underwent Spinal Fusion Surgery

Lead Sponsor:

Xijing Hospital

Collaborating Sponsors:

Shenzhen Hospital of Southern Medical University

Second Xiangya Hospital of Central South University

Conditions:

Degenerative Spinal Disease

Elderly Patients

Eligibility:

All Genders

75+ years

Phase:

NA

Brief Summary

This study aims to evaluate the value of preoperative risk factor evaulation combined with perioperative ERAS measures in improving the clinical prognosis of elderly patients undergo the spinal fusion...

Detailed Description

Population ageing is rapid progressing globally. In the United States, the number of people over the age of 80 is expected to grow from 1.9% in 2020 to 4.3% in 2050. According to the Statistical Commu...

Eligibility Criteria

Inclusion

  • Age ≥75 years old;
  • Have degenerative spinal diseases, including cervical, thoracic and lumbar spine diseases;
  • With severe neurological symptoms fail to conservative treatment and have to undergo the spinal fusion surgery;
  • No serious cognitive impairment (MoCA score ≥8);
  • No surgical contraindications;
  • Anesthesia assessment patients can safely undergo surgery;
  • Patients who voluntarily participate in and sign informed consent, can independently complete effective questionnaires, and are willing to follow up according to clinical requirements.

Exclusion

  • Patients who could not cooperate with doctors to complete preoperative evaluation and postoperative follow-up;
  • Patients requiring spinal intervention due to spinal infection, fracture or metastatic disease;
  • Patients with cerebrovascular accidents in the last 30 days;
  • Patients with hepatic encephalopathy or acute active hepatitis;
  • Patients with severe renal insufficiency with creatinine\>2.5mg/dL or undergoing hemodialysis;
  • Patients with severe lung and cardiovascular diseases, coagulation disorders, and anesthesia contraindications;
  • Patients with poorly controlled diabetes (HBAlc\>8.0%);
  • Patients who are participating in clinical trials of other drugs or medical devices;
  • Patients requiring emergency surgery;
  • Patients who are considered by the investigator to be unable to participate in this clinical trial due to other circumstances.

Key Trial Info

Start Date :

October 15 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 31 2027

Estimated Enrollment :

5000 Patients enrolled

Trial Details

Trial ID

NCT06607081

Start Date

October 15 2024

End Date

October 31 2027

Last Update

September 23 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Xijing Hospital

Xi'an, Shaanxi, China, 710032

2

Xijing Hospital

Xi'an, Shaanxi, China, 710032